From GlobeNewswire: 2025-06-27 15:28:00

RetinalGenix Technologies Inc. has partnered with LabCorp to launch the RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform. This program allows patients to undergo genetic testing and high-resolution retinal imaging to detect both ocular and systemic diseases. Patients can visit LabCorp locations in the USA for sample collection and analysis. The CEO, Jerry Katzman, aims to lower healthcare costs and improve patient access to necessary evaluations. The company plans to introduce high-resolution retinal imaging at more locations to enhance diagnostic accuracy and make screening more accessible and cost-effective.

The collaboration with LabCorp enables patients to maintain control of their health records and receive results securely. Dr. Larry Perich, DO, believes that as disease-associated biomarkers expand, these platforms will improve outcomes and accessibility. Dr. Taimour Langaee, PhD, is excited about the potential to discover new genetic variants and treatments for eye diseases. RetinalGenix’s innovations aim to streamline the patient assessment process and reduce reliance on expensive diagnostic procedures.

The RetinalGenix DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform will provide insights into ocular and systemic diseases, correlating genetic and retinal biomarkers for early detection. The company’s goal is to revolutionize disease detection and improve patient outcomes by integrating advanced imaging and therapeutic development. These technologies are designed to prevent blindness by detecting physiological changes indicating future ocular and systemic diseases. Overall, RetinalGenix is committed to advancing precision medicine in eye diseases and developing therapeutic drugs for various conditions.



Read more at GlobeNewswire: RetinalGenix Technologies Contracts with LabCorp to Support